IMUX Earnings — Immunic, Inc. Common Stock Post-ER Performance | BigEarnings
IMUX — Immunic, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$14.96
Market Cap$203.8M
P/E—
52W Range$5.06 – $15.77
Next Earnings2026-08-06
About Immunic, Inc. Common Stock
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
